[HTML][HTML] Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
ABSTRACT Background In LUX-Lung 7, the irreversible ErbB family blocker, afatinib,
significantly improved progression-free survival (PFS), time-to-treatment failure (TTF) and …
significantly improved progression-free survival (PFS), time-to-treatment failure (TTF) and …
[HTML][HTML] Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
L Paz-Ares, EH Tan, K O'Byrne, L Zhang… - Annals of …, 2017 - ncbi.nlm.nih.gov
Background In LUX-Lung 7, the irreversible ErbB family blocker, afatinib, significantly
improved progression-free survival (PFS), time-to-treatment failure (TTF) and objective …
improved progression-free survival (PFS), time-to-treatment failure (TTF) and objective …
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
L Paz-Ares, EH Tan, K O'Byrne… - Annals of oncology …, 2017 - pubmed.ncbi.nlm.nih.gov
Background In LUX-Lung 7, the irreversible ErbB family blocker, afatinib, significantly
improved progression-free survival (PFS), time-to-treatment failure (TTF) and objective …
improved progression-free survival (PFS), time-to-treatment failure (TTF) and objective …
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
L Paz-Ares, EH Tan, K O'Byrne, L Zhang… - ANNALS OF …, 2017 - scholarworks.bwise.kr
Background: In LUX-Lung 7, the irreversible ErbB family blocker, afatinib, significantly
improved progression-free survival (PFS), time-to-treatment failure (TTF) and objective …
improved progression-free survival (PFS), time-to-treatment failure (TTF) and objective …
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.
L Paz-Ares, EH Tan, K O'Byrne, L Zhang… - Annals of Oncology …, 2017 - europepmc.org
Background In LUX-Lung 7, the irreversible ErbB family blocker, afatinib, significantly
improved progression-free survival (PFS), time-to-treatment failure (TTF) and objective …
improved progression-free survival (PFS), time-to-treatment failure (TTF) and objective …
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
L Paz-Ares, EH Tan, K O'Byrne, L Zhang… - Annals of …, 2017 - eprints.qut.edu.au
Background In LUX-Lung 7, the irreversible ErbB family blocker, afatinib, significantly
improved progression-free survival (PFS), time-to-treatment failure (TTF) and objective …
improved progression-free survival (PFS), time-to-treatment failure (TTF) and objective …
[引用][C] Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
L Paz-Ares, EH Tan, K O'Byrne, L Zhang, V Hirsh… - Annals of …, 2017 - cir.nii.ac.jp
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell
lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial | CiNii Research CiNii …
lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial | CiNii Research CiNii …
[PDF][PDF] Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
L Paz-Ares, EH Tan, K O'Byrne, L Zhang, V Hirsh… - core.ac.uk
Background: In LUX-Lung 7, the irreversible ErbB family blocker, afatinib, significantly
improved progression-free survival (PFS), time-to-treatment failure (TTF) and objective …
improved progression-free survival (PFS), time-to-treatment failure (TTF) and objective …
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
L Paz-Ares, EH Tan, K O'Byrne, L Zhang… - Annals of …, 2017 - annalsofoncology.org
ABSTRACT Background In LUX-Lung 7, the irreversible ErbB family blocker, afatinib,
significantly improved progression-free survival (PFS), time-to-treatment failure (TTF) and …
significantly improved progression-free survival (PFS), time-to-treatment failure (TTF) and …
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: Overall survival data from the phase IIb LUX-Lung 7 trial
L Paz-Ares, EH Tan, K O'Byrne, L Zhang… - Annals of …, 2017 - snucm.elsevierpure.com
Background: In LUX-Lung 7, the irreversible ErbB family blocker, afatinib, significantly
improved progression-free survival (PFS), time-to-treatment failure (TTF) and objective …
improved progression-free survival (PFS), time-to-treatment failure (TTF) and objective …